Why We Need a New Outcomes-Based Value Attribution Framework for Combination Regimens in Oncology
- 14 August 2022
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 25 (11), 1821-1827
- https://doi.org/10.1016/j.jval.2022.06.009
Abstract
No abstract availableKeywords
Funding Information
- Amgen
This publication has 6 references indexed in Scilit:
- Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi‐stakeholder, international workshopBMC Health Services Research, 2021
- Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicineBiomedicine & Pharmacotherapy, 2020
- Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task ForceValue in Health, 2020
- Challenges in the value assessment, pricing and funding of targeted combination therapies in oncologyHealth Policy, 2019
- Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New InnovationsApplied Health Economics and Health Policy, 2018
- Opportunities and Challenges in the Development of Experimental Drug Combinations for CancerJNCI Journal of the National Cancer Institute, 2011